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Objective: Herein,we report a caseof ovarian serous carcinomawithparaneoplastic cerebellardegeneration.
Case report: A 44-year-old female presented to our hospital with dizziness, slurred speech, and ataxic
gait. Brain magnetic resonance imaging was normal. A lumbar puncture revealed a normal cell count in
the cerebrospinal ﬂuid, but slightly elevated protein. Her serum cancer antigen -125 level was high
(2126.4 U/mL), and abdominal computed tomography disclosed a pelvic mass measuring 11 cm in
diameter. Exploratory laparotomy was then performed, and a frozen section of the tumor revealed serous
carcinoma.
Conclusion: According to the surgical ﬁndings and pathological report, The International Federation of
Gynecology and Obstetrics (FIGO) Stage IIIC, Grade 3, serous-type ovarian cancer was diagnosed. Due to
the abovementioned symptoms and signs, we performed a serial test to document the presence of anti-
Yo antibody in this patient.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Case report
A 44-year-old previously healthy female experienced an episode
of slurred speech and dizziness 3 months previously. Two weeks
later, she suffered from lightheadedness, unsteady gait, and bilat-
eral clumsiness of the hands. Her symptoms gradually worsened
until she was unable to sit, stand, or walk without help. No
cognitive decline, headache, fever, nausea, vomiting, double vision,
sensory loss, or sphincter dysfunction was noted. She denied any
history of smoking, drinking alcohol, or taking illicit drugs. There
was no family history of movement or gait disorders.
Initially, she visited our otolaryngology outpatient clinic where a
Hallpike procedure for Benign paroxysmal positional vertigo
(BPPV) was performed with negative results. Mild dysmetria on the
ﬁnger-to-nose test and also a mildly ataxic gait were noted. No
nystagmus or loss of hearing function was identiﬁed. She wasital, Number 92, Section 2,
).
rs.
bstetrics & Gynecology. Publishedadmitted for further evaluation of the dizziness and possible cen-
tral vertigo. During admission, a physical examination was unre-
markable except for the neurological tests. She was alert and
oriented, and had normal cognitive function. Severe dysarthria was
noted; however, the other cranial nerves were grossly unremark-
able. Her extraocular movements were full, and no nystagmus or
KaysereFleischer rings were noted. Muscle power, sensory exam-
ination, and deep tendon reﬂexes were normal, and no Babinski
sign was noted. She had dysmetria and dysdiadochokinesia of
both arms, which was more severe in the left side. She also had a
wide-based gait, truncal ataxia, and bilateral dysmetria on the
heelekneeeshin test.
The presentation was consistent with progressive cerebellar
dysfunction. Magnetic resonance imaging of the brain and cervical
spinal cord did not show any speciﬁc ﬁndings. Cerebrospinal ﬂuid
obtained from lumbar puncture revealed a normal cell count, but
slightly elevated protein (64 mg/dL), indicating an inﬂammatory
process or autoimmune disease. In addition, autoimmune proﬁle,
thyroid proﬁle, and ceruloplasmin level were all within the normal
ranges; however, serum tumor markers were elevated, including
cancer antigen (CA)-153 level of 132.6 U/mL and CA-125 level ofby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Western blot of lysates from mouse cerebellar tissues probed by plasma from
this patient, other cancer patients, and healthy donors. The ﬁrst lane revealed a speciﬁc
band (arrow) indicating a speciﬁc protein in the cerebellar tissue detected by the
patient's plasma.
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Unexpectedly, an abdominal computed tomography scan revealed
a pelvic mass with solid components, measuring 11 cm in diameter,
with suspected liver surface and diaphragm tumor seeding.
Due to the above gynecologic ﬁndings, exploratory laparotomy
was arranged, during which an ovarian serous carcinoma with
peritoneal seeding (including the liver surface, diaphragm, rightFig. 2. Western blot of lysates from this patient's ovarian cancer tissue probed by plasma fr
speciﬁc band (arrow) indicating a speciﬁc protein in the ovarian tissue detected by the pa
plasma from this patient, other cancer patients, and healthy donors. The ﬁrst lane showed a
CDR2 ¼ cerebellar degeneration-related protein 2.
Fig. 3. Immunohistochemical staining on mouse cerebellar tissue. Microscopically, it revea
staining in the tissue stained by the healthy donor's plasma.ascending colon, and omentum) was found, and optimal debulking
surgery was subsequently performed. Permanent pathology
revealed ovarian serous carcinoma, and she was diagnosed with
FIGO Stage IIIC (pT3cNxMb), Grade 3 serous ovarian carcinoma. She
then received consecutive adjuvant chemotherapy.
We then performed a series of examinations on her serum and
tumor specimen. All Western blotting results indicated the pres-
ence of anti-cerebellar degeneration-related protein 2 (CDR2) (Yo)
protein in her plasma (Figs. 1 and 2). To further conﬁrm the pres-
ence of anti-Yo antibodies targeting neural elements, immunohis-
tochemical staining on mouse cerebellar tissue was performed
(Fig. 3). Microscopically, the ﬁndings revealed positive staining of
Purkinje cells in the mouse cerebellar tissue with the patient's
plasma, but not with the plasma from a healthy patient.
Discussion
Paraneoplastic cerebellar degeneration (PCD) is a rare disorder
affecting the neurological system, which is neither metastasis nor
direct tumor invasion to the nervous system, caused by the
immune-mediated effects of cancer [1]. Cerebellar dysfunction is
one of the most common paraneoplastic presentations of cancer.
The following symptoms are necessary to deﬁne classical cerebellar
syndrome: development of a severe pancerebellar syndrome in<12
weeks, with no magnetic resonance imaging evidence of cerebellar
atrophy [2]. The associated symptoms are ataxia, diplopia,
dysphagia, dysarthria, and the prodrome of dizziness, nausea, and
vomiting [3].
The most commonly associated antibodies with tumors are
Hodgkin's lymphoma (anti-Tr and anti-mGluR1), lung cancer (anti-
Hu), and gynecological and breast cancers (anti-Yo and anti-Ri,om this patient, other cancer patients, and healthy donors. (A) The ﬁrst lane revealed a
tient's plasma. (B) Western blot of human CDR2 (Yo) recombinant protein probed by
speciﬁc band (arrow) indicating anti-CDR2 (Yo) antibody within the patient's plasma.
led: (A) positive staining of Purkinje cells stained by this patient's plasma, and (B) no
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leading to apoptosis of Purkinje cells, which is associated with PCD
[6].
PCD is an immune-mediated syndrome, and initial removal of
the source of the antigens by treating the underlying tumor should
be performed [1]. Besides antitumor treatment, immunotherapy
such as plasmapheresis, intravenous immunoglobulin, corticoste-
roids, cyclophosphamide, tacrolimus, or rituximab could be
considered [7]. This patient received four courses of plasmapheresis
and complete courses of chemotherapy, after which her CA-125
level returned to normal range but her cerebellar symptoms per-
sisted. Some studies have reported that PCDwith anti-Yo antibodies
has a better outcome with reversal of neurological symptoms than
other types of antibodies [4,8]. In some cases, complete antitumor
and immune treatment could prevent disease progression but not
reverse the neurological disorders, as in our patient.
In conclusion, we report PCD in a patient with advanced ovarian
cancer. We also provide direct evidence showing the presence of an
anti-Yo antibody in the patient's plasma targeting cerebellar Pur-
kinje cells. This report will help diagnose such cases of paraneo-
plastic syndrome in the future.Conﬂicts of interest
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